Al-Salam Journal for Medical Science
Journal Homepage: http://journal.alsalam.edu.iq/index.php/ajbms
E-ISSN: 2959-5398, P-ISSN: 2958-0870

Specifying Drug Resonance Chemotherapy: A Review

Shamsalmiluk M. Abdulghani[1] *, Athraa A. Mohammed[2], Zahraa M. Alkhateeb[3], Safa Al-shattawi[2], Marwa A. hussein[4], Abbas K. Abbas[5], Nadhum H. Safir[6]

[1]Iraqi center for cancer research and medical genetics, Mustansiriyah University, Baghdad, Iraq.
[2]Department of Forensic Chemistry, Higher Institute of Forensic Sciences, Al-Nahrain University, Baghdad, Iraq.
[3]Department of Chemistry and Clinical Biochemistry, College of Medicine, Mustansiriyah University, Baghdad, Iraq.
[4]Department of Forensic Biology, Higher Institute of Forensic Science, Al-Nahrain University, Baghdad, Iraq.
[5]Muthana Agriculture Directorate, Ministry of Agriculture, Al-Muthana, Iraq.
[6]Department of engineering, Higher Institute of Forensic Science, Al-Nahrain University, Baghdad, Iraq.

*Corresponding Author: Shams almiluk M. Abdulghani

DOI: https://doi.org/10.55145/ajbms.2025.04.02.006
Received March 2025; Accepted July 2025; Available August 2025

ABSTRACT: Drug Resonance Chemotherapy (DRC) is an emerging therapeutic approach designed to enhance the precision and efficacy of cancer treatment by leveraging molecular resonance phenomena. Unlike conventional chemotherapy, which often results in systemic toxicity and multidrug resistance due to its non-specific action, DRC proposes a targeted mechanism wherein chemotherapeutic agents are modulated to interact with cancer cells at specific vibrational frequencies. This method theoretically improves drug-cell binding and reduces off-target effects. The review explores the foundational challenges in cancer therapy, particularly drug resistance caused by genetic mutations, epigenetic changes, efflux pumps, and phenotypic adaptations. DRC incorporates elements of nanotechnology, quantum chemistry, and biophysics to enhance drug delivery, increase bioavailability, and allow for controlled release at tumor sites. The manuscript discusses potential applications of DRC in malignancies such as breast, lung, leukemia, and glioblastoma; however, it notes that empirical evidence remains limited and primarily theoretical. While some early-stage studies and related technologies, like focused ultrasound and nanocarriers, suggest a promising future for resonance-based therapies, the clinical translation of DRC is still in its infancy. Challenges such as high implementation costs, technical complexity, and lack of regulatory clarity also hinder immediate adoption. Nevertheless, DRC represents a potentially transformative direction in oncology by aligning therapeutic specificity with personalized medicine. The review underscores the need for further experimental validation, mechanistic clarification, and clinical trials to establish DRC as a viable alternative or adjunct to traditional chemotherapy strategies.
.

Keywords: Cancer Treatment, Drug Resonance Chemotherapy, Molecular Resonance, Nanotechnology

1. INTRODUCTION

In 2023, it is estimated that there were around 1,958,310 new cancer cases and 609,820 cancer-related deaths in the United States. It includes a variety of disorders that may impact any organ when aberrant cells proliferate uncontrolled and disseminate to other organs [1]. The rate of cancer is rising globally, resulting in considerable physical, psychological, and financial strain on people, families, communities, and healthcare systems. Given the significant incidence and mortality associated with cancer, there is an urgent need for more effective preventive and treatment strategies [2]. Timely identification of malignant tumors enables the effective treatment of about one-third of patients with localized interventions such as surgery or radiation. A systemic chemotherapy strategy is essential for the remaining patients to ensure good cancer care [3].

Resistance to drugs in cancer treatment presents significant challenges, as it enables cancer cells to evade therapeutic effects and sustain their survival. This complexity arises from a combination of genetic, epigenetic, and

phenotypic mechanisms [4]. Genetically, cancer cells may acquire mutations in key genes such as those encoding enzymes and receptors that regulate growth, survival, or repairing DNA damage, allowing them to resist treatment-induced damage [5]. Mutations in apoptotic pathway genes can also enhance the cells' ability to avoid programmed cell death. Epigenetic changes, including altered gene expression without changes in DNA sequence, may silence tumor suppressor genes or activate pro-survival genes, further supporting resistance. Mechanistically, cancer cells often utilize efflux pumps, such as ATP-binding cassette (ABC) transporters, to expel chemotherapeutic agents and reduce intracellular drug concentrations [6]. In addition, phenotypic adaptations, such as adopting a stem cell-like state or entering dormancy, render these cells less responsive to therapies targeting rapidly dividing populations. These survival strategies operate synergistically, making tumor control more difficult and necessitating the development of novel, targeted therapeutic approaches to overcome resistance [7].

Cancer cells develop drug resistance through a combination of intrinsic survival mechanisms and influences from their surrounding microenvironment. They frequently activate pro-survival signaling pathways such as PI3K-Akt-mTOR, which enhance their ability to endure therapeutic stress and avoid apoptosis [8]. At the same time, they may suppress pathways that would normally trigger cell death [9]. Environmental factors like tumor hypoxia, acidic pH, and nutrient deprivation further promote resistance by creating conditions that favor cellular adaptation and survival. These factors, together with genetic and epigenetic changes, allow cancer cells to withstand treatment, emphasizing the complexity of overcoming resistance and the need for targeted therapeutic strategies, as shown in Figure 1 [10].



FIGURE 1. - Visual representation: comprehending mechanisms of drug resistance and novel approaches to surmount them

Panel (A) delineates the principal causative factors leading to drug resistance, including gene mutations, efflux pumps, modifications in signaling pathways, and tumor heterogeneity. Panel (B) presents a variety of modern therapeutic modalities designed to combat the adverse consequences of drug resistance in cancer cells, including targeted therapies, immunotherapies, combination treatments, and novel molecular interventions [10].

Targeted treatments are a new technology in the field of oncology. They use a specific approach in dealing with cancer by focusing on the particular molecular flaws and mechanisms that stimulate cancer growth. Unlike standard chemotherapy, which affects both cancerous and healthy tissues, targeted treatments are designed to focus on the chemicals or pathways that are active in cancerous cells [11]. These treatments are based on the understanding that cancer is not a single disease but a collection of multiple diseases that vary in their genetic and other key features. One of the greatest advantages that targeted therapies offer is the ability to manage drug resistance, one of the greatest challenges faced today that renders most treatments ineffective. These medications that transform the level of drug resistance can, therefore, utilize the mechanism of treatment evasion that cancer cells utilize, thus more effective the effectiveness of treatment [12]. Figure 2 shows numerous approaches that enhance targeted therapy in the management of drug resistance [13].



FIGURE 2.- Analyzing the molecular mechanisms of resistance to drugs in cancer cells: novel concepts for overcoming resistance difficulties, identifying causal drivers vs using sophisticated tools and approaches for combating drug resistanc [13]

Conventional chemotherapy remains used to inhibit the dissemination of cancer cells throughout the patient's body; nevertheless, the medications lack selectivity, destroying both malignant and healthy cells. Consequently, the body's healthy cells experience less functionality and adverse symptoms such as tiredness, alopecia, nausea, emesis, and reduced appetite. These adverse effects diminish the patient's quality of life and may influence the therapy trajectory [14]. Recent research has resulted in the creation of drug delivery systems using nanocarrier-based treatments, which provide several advantages, including diminutive size, prolonged circulation duration, and systemic stability. Utilizing nanocarriers, these drug delivery techniques aim to minimize the systemic toxicity of delivered medications or nanocarriers while ensuring a consistent concentration at the targeted region. A multitude of nanomaterials responsive to endogenous and exogenous stimuli have been developed to enhance their medicinal effectiveness [15].

DRC is a newer method of treatment that uses principles of resonance and molecular interactions to increase the efficacy of chemotherapeutic agents, which depend on these frequencies and are hypothesized based on molecular or vibrational profiles of cancer cells (inspired by quantum biology and biophysics). However, no standardized clinical method currently exists. This reflects the speculative and experimental nature of DRC. DRC differs from conventional chemotherapy, which dispenses cytotoxic drugs through the blood circulation to destroy cancer cells that divide rapidly. DRC uses molecular resonance phenomena to achieve more effective drug binding and specificity while minimizing unwanted side effects. This strategy combines concepts of quantum chemistry, biophysics, nanotechnology, and so on, to more effective the volume and action of the anticancer drugs in cancer tissues [16].

In this case, "resonance" refers to the phenomenon where a tailored therapeutic molecule is created to interact proficiently with a malignant cell at a specific vibrational frequency. This link enhances the absorption of a medication by a biomolecule, increases the efficiency of binding to the target molecules, and decreases the damage to normal cells. DRC intends to deal with the principal shortcomings of traditional chemotherapy, such as systemic toxicity, multidrug resistance, and non-specific targeting of cells. Research in this area of medicine is ongoing, and positive results suggest its use in some cancer conditions [17].

2. COMPOSITION AND MECHANISM OF DRUG RESONANCE CHEMOTHERAPY

The composition and mechanism of Drug Resonance Chemotherapy (DRC) represent a novel and experimental approach to cancer treatment that integrates principles from quantum chemistry, nanotechnology, and molecular biophysics. DRC typically involves conventional chemotherapeutic agents that are enhanced with resonance-based stimulants, such as electromagnetic frequency modulators or nanoparticles, designed to increase the precision and efficiency of drug-cell interactions. The central concept is that these agents can be tuned to “resonate” at specific frequencies that align with the molecular or structural characteristics of malignant cells [18]. This theoretical resonance is proposed to elevate the energy states of the drug molecules, more effective their binding affinity to target sites on cancer cells, thereby allowing more effective drug uptake at lower doses and reducing systemic toxicity. However,

despite its conceptual promise, the DRC mechanism lacks robust experimental validation and currently exists more as a speculative framework than an established scientific process [19].

3. DRUG RESONANCE CHEMOTHERAPY APPLICATIONS

Drug Resonance Chemotherapy (DRC) is proposed as a novel therapeutic approach that combines traditional chemotherapy agents with resonance-based stimulants, such as electromagnetic frequency modulators or nanoparticles, to enhance drug-cell interactions. The central hypothesis suggests that these agents can be tuned to resonate at specific frequencies, aligning with the molecular characteristics of cancer cells, potentially more effective drug uptake and efficacy while minimizing systemic toxicity. While the theoretical framework of DRC is intriguing, empirical evidence supporting its effectiveness across various cancers remains limited. For instance, a study explored the feasibility of designing resonance chemotherapeutic treatments to preferentially eliminate specific leukemia cell lines, indicating potential in this area. However, comprehensive preclinical or clinical data validating DRC's effectiveness in cancers such as breast, lung, or glioblastoma are lacking [20]. Advancements in related fields offer some insights. For example, focused ultrasound (FUS) combined with drug-loaded microbubbles has shown promise in enhancing drug delivery to glioblastoma cells, suggesting that resonance-based methods can more effective therapeutic outcomes. Additionally, the integration of nanotechnology in chemotherapy has demonstrated benefits like increased drug stability and controlled release, which align with the goals of DRC.

Despite these advancements, the specific mechanisms by which DRC operates, particularly the concept of drugs "oscillating at frequencies matching cancer cell architecture," remain speculative without robust scientific validation. To establish DRC as a credible therapeutic modality, extensive research is needed to elucidate its mechanisms and substantiate its efficacy through rigorous preclinical and clinical studies [21].

Zvia Agur, and et al., (2012), Drug Resonance Chemotherapy (DRC) is based on the Resonance theory, which posits that drug administration should align with the cell population's characteristic periodicity to maximize efficacy and minimize toxicity, utilizing cell-cycle phase-specific drugs for optimized treatment outcomes. Personalized regimen increased patient longevity and quality of life, and optimal drug scheduling tailored to individual tumor characteristics [22].

Z. Agur., (2012), More effective cancer treatment efficacy through resonance and anti-resonance methods and reduced toxicity to normal cells with rational drug scheduling [22].

Gabriella Fabbrocini (2015). New chemotherapeutic agents more effective cancer treatment efficacy, and dermatologic adverse events affect patients' quality of life [23].

Lianbo Li (2022). DEB-BACE and anlotinib show promising efficacy in advanced NSCLC, and combination therapy has tolerable toxicity in patients [24].

Traditional chemotherapy has long served as a foundational cancer treatment, employing cytotoxic agents that target rapidly dividing cells to suppress tumor growth. However, its non-selective mechanism often leads to significant systemic toxicity, affecting healthy cells and causing adverse effects such as nausea, alopecia, fatigue, and immunosuppression. Additionally, chemotherapy is frequently limited by multidrug resistance (MDR), where cancer cells evolve mechanisms, such as efflux pumps and genetic mutations, to evade drug action, reducing therapeutic efficacy over time. In contrast, Drug Resonance Chemotherapy (DRC) introduces a novel, targeted approach that aims to overcome these limitations by aligning chemotherapeutic agents with specific vibrational frequencies of cancer cells. This resonance-based interaction theoretically enhances drug absorption, binding specificity, and intracellular efficacy while minimizing off-target damage. DRC also leverages nanotechnology to more drug stability, bioavailability, and controlled release, thus enabling precise tumor targeting and reducing harm to surrounding healthy tissue. Furthermore, DRC shows potential in addressing MDR by altering cellular uptake mechanisms and interfering with resistance pathways. Although still in its conceptual and early experimental stages, DRC offers a promising advance in oncology, particularly in its capacity to provide personalized, less toxic, and potentially more effective treatment regimens compared to traditional chemotherapy. Robust clinical validation is still required.

4. EFFECTS OF DRUG RESONANCE CHEMOTHERAPY, RELATIVE TO TRADITIONAL APPROACHES

Unlike classical chemotherapy, Drug Resonance Chemotherapy provides increased selectivity by directly attacking the cancer cells at precise resonance frequencies. This way, healthy tissues are spared and the specificity of the pharmacological instrument is harnessed to a lower dosage to evoke the therapeutic response, thus reducing the medicine's systemic toxicity and the drug's other side effects, including immune suppression and organ damage [25]. Furthermore, the DRC proficiently addresses multidrug resistance by interfering with resistance mechanisms in cancer cells, rendering previously untreatable malignancies more amenable to therapy. The optimized molecular interactions in the DRC more effective medication delivery and therapeutic effectiveness at reduced dosages. Due to its capacity for personalized treatment, DRC may be customized for individual patients according to their tumor's genetic profile, signifying a notable advance in precision oncology. Moreover, its incorporation with developing technologies like nanomedicine, electromagnetic therapy, and bioinformatics facilitates the creation of comprehensive treatment

regimens, hence enhancing its potential in contemporary cancer therapy. In biophysics, while cells and molecules can exhibit vibrational modes (e.g., Raman scattering, IR spectroscopy), these are typically not used to guide chemotherapy in clinical settings. No established framework or technology in current oncology maps vibrational frequencies of tumors to optimize chemotherapeutic targeting. To support this claim, the authors would need to reference experimental studies or theoretical models from disciplines like quantum biology or nanomedicine demonstrating how resonance frequencies are measured, personalized, and applied to guide drug delivery or selectivity [26].

5. NEGATIVE EFFECTS AND LIMITS OF DRUG RESONANCE CHEMOTHERAPY

Although DRC is fundamentally sound, its application on a broad scale will be hindered by a multitude of factors. Transitioning to DRC from the standard chemotherapy model is not very straightforward due to specialized equipment and required frequency settings. Alongside this, the overall expense of treatment gets hiked significantly with the addition of quantum dots and electromagnetic modulators, making treatment less affordable for most people. Although the preclinical work is encouraging, the safety and efficacy of the DRC is yet to be determined in a wide range of clinical settings. Moreover, because of the novel perspective approach, it is likely prone to extensive regulatory indecision that might slow down the time to market. The improper setting of the resonance frequency is another reason for concern, as it may produce off-target effects and untoward events [27].

In addition, implementing the DRC, especially after standard chemotherapy, radiation therapy, or immunotherapy, will require further interrogation to rule out any negative synergism. The successful adoption of the DRC into the broader field of oncology is bound to happen, provided these issues are dealt with by rigorous research, new technologies, and sensible regulations [27].

Chemotherapy serves as a primary treatment option for cancer and can sometimes yield beneficial results. The clinical consequences of chemotherapy are demonstrated in the insufficient delivery of the drug to the tumor site and serious systemic side effects, which could cause reoccurrence of the tumor and metastases. The delivery of chemotherapeutic agents has more effective due to nanotechnology, using the increased permeability and retention (EPR) effect to increase retention duration and particle accumulation at tumor sites via passive targeting methods. This not only more treatment effectiveness but also minimizes harm to normal tissues. Nonetheless, the breakdown and metabolism significantly constrain nanoplatforms and chronic toxicity of nanomaterials inside the body, presenting a critical obstacle for their prospective therapeutic uses [20].

The therapeutic effect of chemotherapy for tumors may be significantly compromised by inadequate drug delivery due to poor and diverse blood flow, as well as high intertumoral pressure affecting big molecules. Consequently, medicines with significant in vitro efficacy often do not display enough action against solid tumors in vivo due to ineffective transference of the medication from plasma to the tumor interstation. The pharmacokinetics of drugs in the tumor microenvironment are influenced by a combination of physiological and drug-specific factors, including the extent of tumor vascularization, the efficacy of drug administration via blood flow, and the stability of the drug throughout transit to and within the tumor's physiological milieu. The movement of drugs over the cellular membrane is contingent upon the hydrophobic characteristics of the medication and, for diminutive charged molecules, on pH differentials across the membrane [20].

In vivo direct measurements of intertumoral drug concentrations are challenging, and conventional pharmacokinetic models fail to include the intricacies of the tumor microenvironment and vascular dynamics. While tissue medication concentrations in tumors may be assessed using a microanalysis device, noninvasive methods for detecting or predicting drug delivery to tumors have yet to be established [21]. MR spectroscopy is the only really noninvasive method, apart from PET, capable of identifying a substance of interest inside the tissue. Recent advancements in MR methods enable the noninvasive measurement of the distribution of specific anticancer drugs inside solid tumors while simultaneously characterizing, using contrast-enhanced MRI, the vascular factors that influence drug delivery. This methodology was used to evaluate the efficacy of paramagnetic contrast agent-enhanced MRI in forecasting medication delivery to solid tumors, using tumor microcirculation characteristics obtained from MRI data in experimental animal tumor models [15, 28].

A fundamental issue with MR spectroscopy is its poor signal-to-noise ratio in detection relative to nuclear medicine techniques. Recent findings from our lab and others indicate that certain anticancer drugs, when provided at clinically relevant levels, may be identified in solid tumors in vivo by MR spectroscopy. Pharmacokinetic investigations of these drugs have been conducted using 19F, 13C, and 1HNMR spectroscopy and imaging [29, 30]. In vivo tests using 19FNMR spectroscopy revealed that 5-fluorouracil, together with its principal metabolites and catabolites, can be identified in both animal and clinical studies. Proton MR spectroscopy was conducted for iproplatin via double quantum coherence selection to isolate drug signals from the overlapping lipid resonance. The labeling of drug molecules with a 13C isotope is a significant alternative that facilitates their MR detection in vivo with minimum alteration of the chemical and biological characteristics of the medication. Various technological methodologies may markedly enhance the detection sensitivity of 13C, making the technique viable for in vivo use [31].

The majority of MR investigations that directly identify chemotherapeutic drugs in tumors have used compounds that may be delivered in large dosages to facilitate detection using MR. Consequently, these compounds are inherently

less hazardous and mostly include substances classified as cytostatic or preventative [32]. Agents that differentiate both specific and nonspecific nonsteroidal anti-inflammatory medications, which have lately garnered considerable interest as possibilities for the prevention and/or therapy of many malignancies, belong to these groups. Among them, 5-fluorouracil is the only chemotherapeutic drug that has been thoroughly investigated in patients using MR. For medications with low concentrations, it may still be feasible to forecast drug pharmacokinetics and spatial distribution with high temporal and spatial precision by using the pharmacokinetics and spatial distribution of a paramagnetic MR contrast agent via dynamic MRI. The limitations of this method are that the chemotherapeutic agent and the paramagnetic MR contrast agent possess analogous transport characteristics, including water/lipid solubility, molecular size, and macromolecular binding affinities, in addition to the same delivery pathways. The investigations were conducted on two distinct tumor models characterized by markedly varied growth rates and doubling durations. The experimental findings indicate a substantial spatial association between the absorption and distribution of the contrast agent and the medication inside the tumor [33].

6. PURPOSE OF DRUG RESONANCE CHEMOTHERAPY IN PATIENTS

The DRC significantly enhances cancer treatment by offering a more precise, effective, and less toxic alternative to traditional chemotherapy. The major goal is to more effective the accuracy of medication administration, ensuring that chemotherapeutic drugs selectively target cancer cells while reducing harm to healthy organs. This leads to enhanced therapeutic benefits and a significant decrease in the devastating side effects often linked to conventional chemotherapy, including nausea, alopecia, and immunological suppression [34].

One of the major functions of the DRC is to address drug resistance, a significant obstacle in cancer. A significant number of cancer patients encounter therapy failure owing to the capacity of cancer cells to acquire resistance to standard pharmaceuticals. Utilizing resonance principles, the DRC enhances medication absorption and undermines resistance mechanisms, making previously untreatable cancers more amenable to treatment. This is especially advantageous for individuals with aggressive or recurring malignancies who have not responded to conventional therapies [34].

Moreover, the DRC allows for the advancement of personalized medicine by permitting the tailoring of therapy to a particular patient's tumor. Physicians can optimize DRC protocols to make them more effective and less harmful by studying a tumor's genetic and molecular features. The use of nanotechnology with DRC enhances drug stability, bioavailability, and controlled release, which guarantees extended therapeutic effect. In general, the DRC offers a greater quality of life to patients through better cancer treatment alternatives. It can revolutionize cancer treatment by increasing survival outcomes, reducing toxicity, and increasing the effectiveness of treatment in situations where conventional chemotherapy is no longer effective [35].

Through the focusing of cancerous cells and increased protection of healthy tissues, several methodologies surpass the DRC in terms of accuracy. Immunotherapy employs the use of checkpoint blockers, and CAR-T cell therapies, which harness the body’s defense system to attack and destroy cancer cells. Chemotherapy precision is augmented by nanoparticle drug delivery systems using controlled drug release and enhanced retention, thereby decreasing peripheral side effects [36]. In addition to photodynamic therapy, there is PDT, where photosensitive substances are activated at malignant tissues to destroy cancerous cells with less overall damage while having external control over when the therapy is turned on [37]. Tumor Treating Fields (TTFields) employ low-level electric fields to disturb the division of cancer cells and in normal tissues so as not to affect healthy tissues. Unlike other malignant diseases, specific targeted noninvasive techniques have become possible in these cases [38]. Compared to DRC, these methods are solutions to cancer diagnosis and management problems that have enhanced the specificity and customizability while minimizing side effects [36].

This study addresses issues related to the implementation of DRC in healthcare settings with a major focus on how DRC is employed in hospitals. Unlike the conventional method of chemotherapy which acts on all types of cells, both healthy and abnormal ones, DRC does [38]. In contrast to traditional chemotherapy, which indiscriminately affects both healthy and diseased cells, DRC utilizes resonance principles to enhance drug selectivity, guaranteeing that chemotherapeutic drugs exclusively target malignant areas while reducing systemic toxicity. This focused strategy diminishes prevalent side effects, including nausea, immunological suppression, and organ damage, markedly enhancing patient quality of life [35]. Furthermore, DRC helps address multidrug resistance, a significant obstacle in oncology, by more effective medication absorption and interfering with resistance mechanisms in cancer cells. Its incorporation with nanotechnology enhances medication delivery, stability, and controlled release, resulting in more effective therapeutic results. Furthermore, DRC corresponds with the rising focus on personalized medicine, enabling oncologists to customize therapies according to a patient's tumor features, hence enhancing therapeutic success rates. By integrating modern scientific concepts with chemotherapy, DRC signifies a prospective advancement in cancer treatment, providing enhanced effectiveness and fewer side effects relative to conventional techniques [37, 38].

7. CONCLUSION

Drug-resonance chemotherapy achieves a significant breakthrough in fighting cancer, such as better selectivity, lower toxicity, and improved therapeutic effects. The DRC has the potential to change the paradigm of cancer treatment using molecular resonance principles, especially when routine chemotherapy has failed. There is still the issue of high expenses, complexity and stringent regulations before large-scale implementation, and ongoing research and clinical work will be essential in proving DRC to be more suitable than conventional chemotherapy, thus, improving the development of cancer treatment in the future.

Funding

None

ACKNOWLEDGEMENT

The authors would like to thank the anonymous reviewers for their efforts.

CONFLICTS OF INTEREST

The authors declare no conflict of interest

REFERENCES

[1] A. C. P. R. S. Committee, "Cancer in 2023," Cancer Discovery, vol. 13, no. 12, pp. 2510–2514, 2023.
[2] M. Ibrahim, Z. Fathalla, A. A. Fatease, A. H. Alamri, and H. Abdelkader, "Breast cancer epidemiology, diagnostic barriers, and contemporary trends in breast nanotheranostics and mechanisms of targeting," Expert Opin. Drug Deliv., vol. 21, no. 12, pp. 1735–1754, 2024.
[3] B. Anghel et al., "Optimizing palliative pelvic radiotherapy in gynecological cancers: A systematic review and analysis," Diagnostics, vol. 14, no. 5, p. 547, 2024.
[4] K. J. Mohammed, A.-S. M. JI, and H. H. Saeed, "Exploring the potential of nanoparticles as a drug delivery system for cancer therapy: A review," Al-Salam J. Med. Sci., vol. 4, no. 1, pp. 37–43, 2025.
[5] H. Jin, L. Wang, and R. Bernards, "Rational combinations of targeted cancer therapies: Background, advances and challenges," Nat. Rev. Drug Discov., vol. 22, no. 3, pp. 213–234, 2023.
[6] B. A. Mengistu et al., "Comprehensive review of drug resistance in mammalian cancer stem cells: Implications for cancer therapy," Cancer Cell Int., vol. 24, no. 1, p. 406, 2024.
[7] T. S. Lima et al., "Itraconazole reverts ABCB1-mediated docetaxel resistance in prostate cancer," Front. Pharmacol., vol. 13, p. 869461, 2022.
[8] R. Wieder, "Fibroblasts as turned agents in cancer progression," Cancers, vol. 15, no. 7, p. 2014, 2023.
[9] T. Hompland, C. S. Fjeldbo, and H. Lyng, "Tumor hypoxia as a barrier in cancer therapy: Why levels matter," Cancers, vol. 13, no. 3, p. 499, 2021.
[10] P. Garg et al., "Emerging therapeutic strategies to overcome drug resistance in cancer cells," Cancers, vol. 16, no. 13, p. 2478, 2024.
[11] B. Liu, H. Zhou, L. Tan, K. T. H. Siu, and X.-Y. Guan, "Exploring treatment options in cancer: Tumor treatment strategies," Signal Transduct. Target. Ther., vol. 9, no. 1, p. 175, 2024.
[12] A. Upadhyay, "Cancer: An unknown territory; rethinking before going ahead," Genes Dis., vol. 8, no. 5, pp. 655–661, 2021.
[13] Y. Shlyakhtina, K. L. Moran, and M. M. Portal, "Genetic and non-genetic mechanisms underlying cancer evolution," Cancers, vol. 13, no. 6, p. 1380, 2021.
[14] E. Orrantia-Borunda et al., "Subtypes of breast cancer," Breast Cancer [Internet], 2022.
[15] S. Akkın, G. Varan, and E. Bilensoy, "A review on cancer immunotherapy and applications of nanotechnology to chemoimmunotherapy of different cancers," Molecules, vol. 26, no. 11, p. 3382, 2021.
[16] J. B. Oehler, W. Rajapaksha, and H. Albrecht, "Emerging applications of nanoparticles in the diagnosis and treatment of breast cancer," J. Pers. Med., vol. 14, no. 7, p. 723, 2024.
[17] A. A. Ansari, A. K. Parchur, and G. Chen, "Surface modified lanthanide upconversion nanoparticles for drug delivery, cellular uptake mechanism, and current challenges in NIR-driven therapies," Coord. Chem. Rev., vol. 457, p. 214423, 2022.
[18] X. Li et al., "Recent development of pH‐responsive theranostic nanoplatforms for magnetic resonance imaging‐guided cancer therapy," Exploration, vol. 3, no. 3, p. 20220002, 2023.
[19] K. Chauhan and R. Rana, "Role of genetic mechanism in cancer," in Advances in Cancer Biomarkers Research. Elsevier, 2025, pp. 17–45.

[20] Y. F. Mustafa, "Chemotherapeutic applications of folate prodrugs: A review," NeuroQuantology, vol. 19, no. 8, pp. 99–113, 2021.
[21] M. Jiang et al., "Construction of magnetic drug delivery system and its potential application in tumor theranostics," Biomed. Pharmacother., vol. 154, p. 113545, 2022.
[22] Z. Agur and Y. Kheifetz, "Optimizing cancer chemotherapy: From mathematical theories to clinical treatment," in New Challenges for Cancer Systems Biomedicine, pp. 285–299, 2012.
[23] G. Fabbrocini, L. Panariello, G. Caro, and G. Monfrecola, "Chemotherapy and cutaneous drug reactions," in Cutaneous Drug Eruptions: Diagnosis, Histopathology and Therapy, pp. 309–321, 2015.
[24] L. Li, "Drug resistance in lung cancer chemotherapy and personalized chemotherapy," Frontiers Media SA, vol. 10, p. 971477, 2022.
[25] M. A. Subhan et al., "Approaches to improve EPR-based drug delivery for cancer therapy and diagnosis," J. Pers. Med., vol. 13, no. 3, p. 389, 2023.
[26] N. Jamaladdin, "The role of key pharmacodynamic and pharmacokinetic parameters in drug response prediction of pediatric tumors in the precision oncology study INFORM," 2023.
[27] Y.-Q. Liu, X.-L. Wang, D.-H. He, and Y.-X. Cheng, "Protection against chemotherapy- and radiotherapy-induced side effects: A review based on the mechanisms and therapeutic opportunities of phytochemicals," Phytomedicine, vol. 80, p. 153402, 2021.
[28] T. Akbar et al., "Use of magnetic resonance imaging for visualization of oral dosage forms in the human stomach: A scoping review," Mol. Pharm., vol. 21, no. 4, pp. 1553–1562, 2024.
[29] D. Middleton, "Conformational analysis of uniformly 13C-labeled peptides by rotationally selected 13Cα-13CH3 double-quantum solid-state NMR," Molecules, vol. 30, no. 3, p. 739, 2025.
[30] Z. A. Ketan et al., "A review of recent developments in pharmaceutical chemistry on biological evolution of tetrazole derivatives," Al-Salam J. Med. Sci., vol. 4, no. 1, pp. 1–8, 2025.
[31] S. Wi et al., "Dynamic nuclear polarization-enhanced, double-quantum filtered 13C-13C dipolar correlation spectroscopy of natural 13C abundant bone-tissue biomaterial," J. Magn. Reson., vol. 335, p. 107144, 2022.
[32] A. N. Al-Thani et al., "Nanoparticles in cancer theragnostic and drug delivery: A comprehensive review," Life Sci., p. 122899, 2024.
[33] S. Liu, W. Wei, J. Wang, and T. Chen, "Theranostic applications of selenium nanomedicines against lung cancer," J. Nanobiotechnol., vol. 21, no. 1, p. 96, 2023.
[34] P. K. Dhanyamraju, "Drug resistance mechanisms in cancers: Execution of pro-survival strategies," J. Biomed. Res., vol. 38, no. 2, p. 95, 2024.
[35] L. Tinger, "Development of an integrated platform for personalized cancer treatment: Diagnostic and therapeutic solutions based on biomarkers and nanotechnology," 2024.
[36] S. Weinstein, "The role of the immune system in carcinogenesis and cancer immunotherapy," J. Carcinog., vol. 23, no. 1, 2024.
[37] N. Sobhani and A. A. Samadani, "Implications of photodynamic cancer therapy: An overview of PDT mechanisms basically and practically," J. Egypt. Natl. Canc. Inst., vol. 33, pp. 1–13, 2021.
[38] S. Shams and C. B. Patel, "Anti-cancer mechanisms of action of therapeutic alternating electric fields (tumor treating fields [TTFields])," J. Mol. Cell Biol., vol. 14, no. 8, p. mjac047, 2022.